Core Viewpoint - Novo Nordisk's Wegovy has received FDA approval for a new indication to treat metabolic associated fatty liver disease (MASH) with moderate to severe liver fibrosis in non-cirrhotic adult patients, marking it as the first GLP-1 drug approved for this condition [1] Group 1 - Novo Nordisk's stock rose nearly 3% to $55.33 following the FDA approval announcement [1] - The approval is based on a supplemental new drug application (sNDA) [1] - Wegovy is now positioned uniquely as the first and only GLP-1 drug approved for treating MASH [1]

Core Viewpoint - Novo Nordisk's Wegovy has received FDA approval for a new indication to treat metabolic associated fatty liver disease (MASH) with moderate to severe liver fibrosis in non-cirrhotic adult patients, marking it as the first and only GLP-1 drug approved for this condition [1] Group 1 - Novo Nordisk's stock rose nearly 3% to $55.33 following the FDA approval announcement [1] - The approval is based on a supplemental new drug application (sNDA) for Wegovy (semaglutide 2.4mg) [1] - The new indication is intended for use alongside dietary control and increased physical activity [1] Group 2 - Martin Holst Lange, the company's Executive Vice President and Chief Scientific Officer, emphasized Wegovy's unique position in the market as the first GLP-1 drug approved for MASH treatment [1]